Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | IGF1R | P08069 | 2/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | PRKX | P51817 | 2/20 | 1.00 |
| ▸ | BTK | Q06187 | 2/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12068009 | 0.79 | PARP1 (0.66) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL29957158 | 0.79 | PARP1 (0.65) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL526730 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL1387233 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL4076857 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL5370073 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL12747755 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL13857872 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL21895445 | 0.78 | PARP1 (1.00) | PARP1AURKADAPK3PRKD3MAP4K4 | |
| SCHEMBL16097896 | 0.78 | PARP1 (0.64) | PARP1AURKADAPK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490461-A | Trifluoromethyl substituted quinazolinone compound, preparation method and application | 平顶山学院 | 2025-02-21 | — | — | CN | disclosed |
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2022233253-A1 | METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS | 杭州星鳌生物科技有限公司 | 2022-11-10 | — | — | WO | disclosed |
| CN-115260164-A | Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-107337646-B | Method for synthesizing quinazolinone derivative by using methanol as raw material | 南京理工大学 | 2020-04-07 | — | — | CN | disclosed |
| CN-107337646-A | A kind of method using methanol as Material synthesis Quinazol derivative | 南京理工大学 | 2017-11-10 | — | — | CN | disclosed |
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | PARP1 3492/4885AURKA 3167/4885DAPK3 1944/4885 |
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | PARP1 3520/4885AURKA 3567/4885DAPK3 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.